Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus SERVISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus SERVISONE.
ASMANEX HFA vs SERVISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
SERVISONE is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to glucocorticoid receptors, modulating gene transcription, and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
10-20 mg orally once daily in the morning; higher doses up to 40 mg daily for severe cases.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Terminal elimination half-life is 3-4 hours. Clinically, this supports twice-daily dosing for sustained effect.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Renal (70-80% as metabolites, 5-10% unchanged); fecal/biliary (15-20%)
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid